Fatty liver disease (NAFLD) is the pathological accumulation of triglycerides exceeding 5% of liver weight in individuals without significant alcohol consumption (<20g/day women, <30g/day men). It represents the hepatic manifestation of metabolic syndrome and Evolutionary mismatch, progressing from simple steatosis through non-alcoholic steatohepatitis (NASH) to Fibrosis and cirrhosis. With prevalence exceeding 60% in general populations and childhood obesity, NAFLD constitutes a global metabolic pandemic.
Imagine your liver as a high-performance engine designed to burn fuel efficiently and produce emergency energy reserves (ketones) when needed. In NAFLD, the engine's fuel tank becomes overfilled with the wrong fuel—like pouring thick vegetable oil into a diesel engine. The excess comes from two sources: too much glucose being converted into fat inside the liver (like a factory making its own inferior fuel), and fat being dumped from overstuffed fat cells throughout the body. As the liver fills with these fat droplets, the engine's machinery—the mitochondria—starts to sputter and overheat, producing smoke (oxidative stress) and setting off fire alarms (inflammatory signals). The maintenance crew (immune cells) rushes in, but instead of fixing the problem, they start building protective walls (fibrosis), which eventually choke off the engine's function. Meanwhile, the emergency fuel system (ketone production) breaks down completely, leaving the body without its metabolic backup generator during fasting. The tragedy is that this entire cascade started simply from running the engine continuously on high-octane fuel (constant carbohydrate intake) without ever letting it switch to fat-burning mode.
Fatty liver disease develops through a multi-hit pathophysiological cascade involving overlapping metabolic, inflammatory, and immune processes:
De novo lipogenesis pathway:
- Chronic hyperinsulinaemia activates SREBP-1c (sterol regulatory element-binding protein-1c)
- SREBP-1c upregulates ACC (acetyl-CoA carboxylase) and FAS (fatty acid synthase)
- Excess Glucose → pyruvate → acetyl-CoA → malonyl-CoA → fatty acid synthesis
- Malonyl-CoA simultaneously inhibits CPT1A (carnitine palmitoyltransferase 1A), blocking mitochondrial fat oxidation
- Fructose bypasses glycolytic regulation, directly feeding de novo lipogenesis via xylulose-5-phosphate activation of carbohydrate response element-binding protein (ChREBP)
Lipolytic overflow:
- Insulin resistance in adipose tissue → uninhibited HSL (hormone-sensitive lipase)
- Free fatty acids released from visceral adipose tissue drain via portal vein directly to liver
- Hepatocyte uptake via CD36 and fatty acid transport proteins (FATPs)
- Triglyceride synthesis exceeds VLDL export capacity
¶ Hepatocellular Stress and Inflammation
Lipotoxicity cascade:
Inflammatory activation:
¶ Progression to NASH and Fibrosis
Immune cell recruitment:
- Hepatocyte-derived CCL2 (MCP-1) recruits monocytes → liver macrophages (Kupffer cells)
- M1 macrophage polarization → amplification of TNF-α, IL-12, IL-1β
- Neutrophil recruitment via CXCL1, IL-8
- NK cell and NKT cell activation
Stellate cell activation:
Failed ketogenesis:
FGF21 resistance:
- Initial compensatory increase in FGF21 secretion from stressed hepatocytes
- Progressive FGF21 receptor downregulation → failed metabolic signaling
- Loss of adipose browning, impaired lipid oxidation, reduced energy expenditure
graph TD
A[Chronic Positive Energy Balance] --> B[Hyperinsulinaemia]
A --> C[Adipose Tissue Insulin Resistance]
B --> D[SREBP-1c Activation]
D --> E[ACC/FAS Upregulation]
E --> F[De Novo Lipogenesis]
B --> G[Fructose Metabolism]
G --> H[ChREBP Activation]
H --> F
C --> I[Lipolysis HSL]
I --> J[FFA Portal Delivery]
F --> K[Hepatic Triglyceride Accumulation]
J --> K
K --> L[Lipotoxicity]
L --> M[Mitochondrial Dysfunction]
L --> N[ER Stress]
M --> O[ROS Production]
N --> O
O --> P[NLRP3 Inflammasome]
Q[Gut LPS/Endotoxemia] --> R[TLR4 Activation]
R --> S["NF-κB"]
P --> S
S --> T["IL-6, TNF-α, IL-1β"]
T --> U[Stellate Cell Activation]
T --> V[Immune Cell Recruitment]
U --> W["TGF-β"]
W --> X[Fibrosis/NASH]
K --> Y[Failed Ketogenesis]
K --> Z[FGF21 Resistance]
Fatty liver disease is the quintessential manifestation of Evolutionary mismatch—a condition virtually absent in hunter-gatherer populations consuming ancestral diets and living physically active lifestyles. It represents a convergence of the selfish brain, Selfish immune system, and metabolic dysregulation:
Five Metamodel Integration:
Clinical Assessment:
- Elevated ALT (>40 IU/L) and AST (>35 IU/L) with ALT:AST ratio >1 in NAFLD (reverses to <1 in cirrhosis)
- Ferritin often elevated (>200 ng/mL) reflecting inflammation and iron dysregulation
- HbA1c >5.7% indicates prediabetic metabolic dysfunction
- Hepatic steatosis index = 8 × (ALT/AST ratio) + BMI (+2 if diabetes, +2 if female) >36 indicates NAFLD
- Fibroscan elastography: <7 kPa normal, 7-10 kPa significant fibrosis, >10 kPa advanced fibrosis
- NAFLD fibrosis score calculator uses age, BMI, glucose, platelets, albumin, AST/ALT
Intervention Strategy:
- Metabolic switching restoration: ketogenic diet, time-restricted eating (16:8 minimum), intermittent fasting protocols to reverse hepatic fat via enhanced β-oxidation and autophagy
- Insulin sensitization: resistance training (critical for GLUT4 translocation), high-intensity interval training, walking after meals
- Gut barrier repair: address dysbiosis with probiotics (Akkermansia-muciniphila, Lactobacillus rhamnosus), reduce LPS burden, eliminate processed foods
- Anti-inflammatory nutrition: omega-3 fatty acids (EPA >2g/day), Curcumin, Resveratrol, eliminate fructose (especially high-fructose corn syrup)
- Hepatoprotective supplements: Silybum marianum (milk thistle), N-acetylcysteine (600mg 2×/day), Vitamin E (800 IU/day), Choline (550mg/day), Betaine
Prognostic Implications:
- NAFLD increases cardiovascular mortality risk by 1.5-2× independent of other metabolic factors
- 20-30% of NAFLD progresses to NASH over 10 years
- 10-20% of NASH progresses to cirrhosis over 10 years
- NASH-cirrhosis carries 7% annual risk of hepatocellular carcinoma
- Reversal is possible: 10% weight loss achieves NASH resolution in ~90% of patients
- Prevalence pandemic: Affects >60% of general population in Western countries; >60% of children with obesity
- Pediatric crisis: NAFLD now leading cause of chronic liver disease in children, reflecting early-life metabolic programming failure
- Fructose specificity: Fructose metabolism bypasses phosphofructokinase regulation, driving hepatic de novo lipogenesis 10× more efficiently than glucose
- Threshold for steatosis: >5% liver weight as fat (approximately >5.5% on proton magnetic resonance spectroscopy)
- NASH criteria: Steatosis + hepatocyte ballooning + lobular inflammation + often fibrosis (requires biopsy confirmation)
- Metabolic flexibility marker: Impaired ketone production during fasting (β-hydroxybutyrate <0.5 mmol/L after 12h fast) signals hepatic dysfunction
- Portal endotoxin: LPS levels in portal vein can be 2-5× higher than systemic circulation in NAFLD patients with Intestinal permeability
- Mitochondrial density: Hepatocytes in NAFLD show 30-50% reduction in mitochondrial density and 40-60% reduction in oxidative capacity
- Reversibility window: Simple steatosis is fully reversible; early NASH is reversible; advanced fibrosis (F3-F4) has limited reversibility
- Exercise dose-response: 150-200 minutes/week moderate-intensity exercise reduces liver fat by 20-30% independent of weight loss
- insulin resistance — primary driver creating hyperinsulinaemia that activates de novo lipogenesis while simultaneously blocking fat oxidation through malonyl-CoA-mediated CPT1A inhibition
- metabolic syndrome — NAFLD is the hepatic component of the metabolic syndrome cluster, sharing pathophysiology with Type 2 Diabetes, hypertension, and dyslipidemia
- de novo lipogenesis — hepatic conversion of excess glucose and fructose to fatty acids via ACC and FAS enzymes overwhelms VLDL export capacity
- NLRP3 inflammasome — activated by cholesterol crystals, ROS, and lysosomal damage in fatty hepatocytes, producing IL-1β that drives progression to NASH
- hepatic ketogenesis — suppressed by chronic hyperinsulinaemia and mitochondrial dysfunction, eliminating the liver's ability to produce ketones during fasting states
- FGF21 — metabolic stress hormone initially elevated as compensatory signal but becomes ineffective through receptor resistance, failing to restore metabolic homeostasis
- mitochondrial dysfunction — lipid overload causes incomplete β-oxidation, electron transport chain impairment, and excessive ROS production
- Oxidative Stress — ROS from dysfunctional mitochondria damage hepatocyte proteins, lipids, and DNA, activating inflammatory cascades
- chronic low-grade inflammation — liver inflammation drives systemic IL-6, TNF-α, and CRP elevation contributing to whole-body insulin resistance
- dysbiosis — altered gut microbiome composition (reduced Akkermansia-muciniphila, increased Enterobacteriaceae) increases LPS production and intestinal permeability
- Intestinal permeability — compromised tight junction integrity allows LPS translocation via portal vein directly to liver, activating TLR4-NF-κB inflammatory cascade
- endotoxemia — elevated circulating LPS from gut barrier dysfunction triggers Kupffer cell activation and hepatic inflammation
- Type 2 Diabetes — NAFLD and diabetes are bidirectional: NAFLD increases diabetes risk 2-5×, while diabetes accelerates NAFLD progression to NASH and fibrosis
- hepatic stellate cells — quiescent vitamin A-storing cells activated by TGF-β from damaged hepatocytes, transdifferentiating to myofibroblasts producing excessive collagen
- ketogenic diet — therapeutic intervention forcing metabolic shift from glucose to fat oxidation, reversing hepatic steatosis by depleting glycogen and activating β-oxidation pathways
- intermittent fasting — activates hepatic autophagy (lipophagy) to break down lipid droplets, enhances mitochondrial biogenesis, and restores metabolic flexibility
- fructose — uniquely lipogenic sugar bypassing glycolytic regulation, directly activating ChREBP to drive hepatic de novo lipogenesis independent of insulin
- sedentary behavior — physical inactivity reduces hepatic fat oxidation, decreases mitochondrial density, impairs insulin signaling, and prevents GLUT4-mediated glucose clearance
- TNF-α — inflammatory cytokine elevated in NAFLD that impairs insulin receptor signaling via serine phosphorylation of IRS-1, creating hepatic and systemic insulin resistance
- cardiovascular disease — NAFLD independently predicts cardiovascular events beyond traditional risk factors, likely through hepatic production of inflammatory proteins and atherogenic lipoproteins
- gut-brain axis — bidirectional signaling where hypothalamic inflammation drives feeding behavior dysregulation while gut-derived signals modulate hepatic metabolism
- Metabolic flexibility — NAFLD represents complete loss of ability to switch between glucose and fat oxidation, manifesting as impaired fasting ketogenesis and postprandial fat storage
- TGF-beta — master profibrotic cytokine released by damaged hepatocytes and activated immune cells, driving stellate cell activation and collagen deposition
- Endoplasmic Reticulum Stress — lipid accumulation triggers unfolded protein response in hepatocytes, activating inflammatory pathways and contributing to hepatocyte apoptosis
- time-restricted eating — confines eating to 8-10 hour window, allowing extended fasting periods that activate hepatic autophagy, ketogenesis, and metabolic switching